EZH2 and cancer: Likewise, doxorubicin and vorinostat were found to interact with EZH2. Thus, these drugs could be useful to target particular hub genes irrespective of the types of cancer and may be added to the therapy to counteract cisplatin resistance once clinical significance is established via pre-clinical/clinical studies.